The Region Of The Imaging Agent Responsible For Binding To An In Vivo Target Or The Region Of The Target Responsible For Binding To The Agent Is Specifically Recited Functionally Or As A Sequence Of Amino Acids, Carbohydrate Residues, Or Nucleic Acids Patents (Class 424/9.341)
-
Patent number: 11238079Abstract: In an auto-classification system, example documents whose content exemplifies a content category or classification can be imported into a classification model. The classification model is tested to assess accuracy. Based on the testing, metrics or other information can be provided as feedback to a user. The user can iteratively refine the classification model and keep re-running the classifications to view how each change to the classification model improves accuracy. If no user refinement is desired, the auto-classification system classifies documents utilizing the classification model. This technology enhances the overall transparency and defensibility of the auto-classification process.Type: GrantFiled: February 11, 2019Date of Patent: February 1, 2022Assignee: OPEN TEXT CORPORATIONInventors: Charles-Olivier Simard, Alex Bowyer, Daniel Leclerc, Steve Molloy
-
Patent number: 10301358Abstract: Compounds and methods for imaging and/or assessing collagen are described. The compounds can include collagen binding peptides.Type: GrantFiled: June 29, 2016Date of Patent: May 28, 2019Assignee: Collagen Medical, LLCInventors: Richard J. Looby, Peter D. Caravan, Thomas J. McMurry
-
Patent number: 9999691Abstract: The present invention provides methods for detecting an enzymatic activity, the method including combining at least one magnetic particle to an enzyme substrate to form a magnetically modified substrate, reacting the magnetically modified substrate with at least one enzyme; and detecting a change in a magnetic property of the magnetically modified substrate or its cleavage products, thereby detecting an activity of said at least one enzyme, wherein the method may be applied to a human subject to detect a disease selected from the group consisting of rheumatitis, arthritis, an injury, Dupuytren's disease, Peyronie's disease, a collagen related disease, steatosis, fibrosis, cirrhosis, metastasis, tissue regeneration, cancer, coronary disease, a liver disease, a metabolic condition, an infection and an inflammatory disease.Type: GrantFiled: December 25, 2013Date of Patent: June 19, 2018Inventor: Julian Daich
-
Patent number: 9409923Abstract: Disclosed is a drug-fluorophore complex for specific detection of tumor cells. Specifically, the drug-fluorophore complex includes a tumor cell-targeting drug penetrating tumor cells and non-tumor cells at different rates or levels, and a fluorescent substance chemically bonded to the tumor cell-targeting drug. The drug-fluorophore complex enables specific imaging of tumor cells only with high accuracy in a very simple manner without causing cytotoxicity.Type: GrantFiled: July 8, 2013Date of Patent: August 9, 2016Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Kwang Meyung Kim, Ick Chan Kwon, Sang Yoon Kim, Ju Hee Ryu, Eun Sung Jun, In San Kim
-
Publication number: 20150132220Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: ApplicationFiled: January 8, 2015Publication date: May 14, 2015Inventors: Philip E. Thorpe, Jin He
-
Publication number: 20150093336Abstract: The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.Type: ApplicationFiled: March 15, 2013Publication date: April 2, 2015Inventors: Jo Van Ginderachter, Patrick De Baetselier, Nick Devoogdt, Tony Lahoutte, Damya Laoui, Kiavash Movahedi, Geert Raes, Steve Schoonooghe
-
Patent number: 8992886Abstract: Compositions, methods of using and methods of making a cyclic peptide analog imaging agent that includes at least portions of a peptide or protein that binds specifically to the GLP-1 receptor (GLP-1R) and the cyclic analog has one or more conformational restrictions including, but not limited to, lactam bridges, disulfide bridges, hydrocarbon bridges, and their combinations, salts and derivatives thereof wherein the cyclic analog is more stable than a non-cyclic analog when incubated in the presence of enzymes that degrade GLP-1 and have an increased serum half-live, wherein the cyclic analog comprises at least a portion of a GLP-1 peptide or at least a portion of an Exendin peptide salts, derivatives or combinations thereof.Type: GrantFiled: April 6, 2010Date of Patent: March 31, 2015Assignee: Board of Regents, the University of Texas SystemInventors: Jung-Mo Ahn, Xiankai Sun
-
Patent number: 8968760Abstract: A method for attaching an implant to tissue is disclosed. In embodiments, a method includes applying a sprayable material to tissue, the sprayable material possessing functional groups capable of binding to tissue. The sprayable material also possesses functional groups capable of binding to an implant. In embodiments, the functional groups capable of binding to an implant include nucleotides. In such a case, the implant possesses complementary nucleotides capable of binding to the nucleotides on the sprayable material, thereby permitting hydrogen binding between the two. The implant may thus be affixed to tissue, and repositioned as necessary, prior to more permanent attachment utilizing means such as sutures, tacks, etc.Type: GrantFiled: February 24, 2012Date of Patent: March 3, 2015Assignee: Covidien LPInventors: Timothy Sargeant, Jonathan Thomas
-
Publication number: 20150056133Abstract: The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.Type: ApplicationFiled: August 20, 2014Publication date: February 26, 2015Inventors: Alisa K. WATERMAN, Nick Mark Devoogdt, Tony Lahoutte, Matthias SCHNEIDER, Sanjaya SINGH, Cedric Jozef Néotère VERVERKEN
-
Publication number: 20140369940Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: June 22, 2012Publication date: December 18, 2014Applicants: University of Zurich, Biogen IDEC International Neuroscience GmbHInventors: Andreas Weihofen, Jan Grimm, Cristoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Publication number: 20140341814Abstract: Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG.Type: ApplicationFiled: April 22, 2014Publication date: November 20, 2014Inventors: Luca Domenico D'Andrea, Carlo Pedone, Maria Caterina Turco
-
Publication number: 20140328753Abstract: Antibodies for molecular imaging of vulnerable plaques in atherosclerosis Antibody specifically binding to atherosclerosis lesions for in vivo imaging and methods for in vivo imaging of atherosclerosis lesions in a patient.Type: ApplicationFiled: November 15, 2012Publication date: November 6, 2014Applicants: UNIVERSITE BORDEAUX SEGALEN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Gisele Clofent-Sanchez, Kamel Deramchia, Marie-Josee Joacobin, Stephane Bonetto, Jeanny Traineau
-
Publication number: 20140286862Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.Type: ApplicationFiled: October 26, 2012Publication date: September 25, 2014Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
-
Patent number: 8821836Abstract: The invention provides SPARC and Albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents. In particular, compositions comprising SPARC binding peptide-Antibody Fc domain fusion proteins and methods of their use are disclosed.Type: GrantFiled: May 17, 2013Date of Patent: September 2, 2014Assignee: Abraxis BioScience, LLCInventor: Vuong Trieu
-
Patent number: 8753610Abstract: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.Type: GrantFiled: April 7, 2010Date of Patent: June 17, 2014Assignee: ArmaGen Technologies, Inc.Inventors: William M. Pardridge, Ruben J. Boado
-
Publication number: 20140161724Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: ApplicationFiled: December 16, 2013Publication date: June 12, 2014Applicant: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Jin He
-
Publication number: 20140127139Abstract: The application relates to a compound of general formula (I) below: Signal-Linker-Peptide??(I) and to the uses thereof for medical imaging or diagnosis or the preparation of a composition for diagnosis of an MUC5AC pathological condition.Type: ApplicationFiled: November 30, 2011Publication date: May 8, 2014Applicant: GuerbetInventors: Sébastien Ballet, Walter Gonzalez, Yannick Rossez
-
Patent number: 8636981Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.Type: GrantFiled: December 7, 2011Date of Patent: January 28, 2014Assignee: Onclave TherapeuticsInventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall
-
Patent number: 8617521Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are therapeutic and diagnostic methods using targeting ligands that bind an irradiated tumor.Type: GrantFiled: August 1, 2011Date of Patent: December 31, 2013Assignee: Vanderbilt UniversityInventors: Dennis E. Hallahan, Raymond Mernaugh
-
Publication number: 20130330279Abstract: The present disclosure provides compositions and methods of treating Breast Cancer. Disclosed is a nanoparticle paired to at least one of W genetic materials that suppress key regulators of fat synthesis (e.g. Rev-erb) to cause a predefined target cell types apoptosis or X predefined targeting moieties that cause predefined target cell types apoptosis and correspond to Y predefined target parameters associated with Z predefined target cell types in connection with treatment of at least one of the following breast cancer, glioblastoma, head and neck cancer, pancreatic cancer, lung cancer, cancer of the nervous system, gastrointestinal cancer, prostate cancer, ovarian cancer, kidney cancer, retina, cancer, skin cancer, liver cancer, genital.Type: ApplicationFiled: December 22, 2012Publication date: December 12, 2013Applicant: NNANOAXIS, LLCInventors: Krishnan Chakravarthy, Robert Spengler, Tracey Ignatowski, Siddhartha Kamisetti
-
Publication number: 20130315823Abstract: The invention provides SPARC and Albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents. In particular, compositions comprising SPARC binding peptide-Antibody Fc domain fusion proteins and methods of their use are disclosed.Type: ApplicationFiled: May 17, 2013Publication date: November 28, 2013Applicant: Abraxis BioScience, LLCInventor: Abraxis BioScience, LLC
-
Publication number: 20130295021Abstract: Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: October 11, 2011Publication date: November 7, 2013Inventors: Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Roger Nitsch, Christoph Hock
-
Patent number: 8551452Abstract: This invention relates to determining the compliance of a subject receiving dietary supplementation with uridine or a uridine source. Specifically, the invention relates to the use of MRS for measuring an increase in brain compounds resulting from dietary supplementation with uridine or a uridine source.Type: GrantFiled: November 3, 2008Date of Patent: October 8, 2013Assignee: Massachusetts Institute of TechnologyInventor: Richard Wurtman
-
Patent number: 8546544Abstract: Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed.Type: GrantFiled: August 30, 2010Date of Patent: October 1, 2013Assignee: Samsung Electronics Co., Ltd.Inventors: Kwang-ho Cheong, Sung-young Jeong, Sang-hyun Paek
-
Publication number: 20130251642Abstract: The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression.Type: ApplicationFiled: November 30, 2011Publication date: September 26, 2013Applicant: The United States of America, as represented by the secretary, Department of Heath and Human ServiInventors: Christoph Rader, Jiahui Yang
-
Patent number: 8529901Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.Type: GrantFiled: June 4, 2008Date of Patent: September 10, 2013Assignee: Hoffmann-La Roche, Inc.Inventors: Max Hasmann, Helmut Lenz, Werner Scheuer
-
Patent number: 8512677Abstract: A method of inhibiting amyloid beta aggregation in a mammal includes administering an amount of a pyro-Glu-(3-40/42)-A? targeting agent and/or fragment thereof that specifically binds to an epitope of the N terminus end of a pyro-Glu-(3-40/42)-A? effective to inhibit amyloid beta aggregation in the subject.Type: GrantFiled: April 27, 2010Date of Patent: August 20, 2013Assignee: Case Western Reserve UniversityInventor: Chris Dealwis
-
Patent number: 8481689Abstract: Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed.Type: GrantFiled: August 30, 2010Date of Patent: July 9, 2013Assignee: Samsung Electronics Co., Ltd.Inventors: Kwang-ho Cheong, Sung-young Jeong, Sang-hyun Paek
-
Publication number: 20130171062Abstract: Provided are compositions and methods for diagnosing eosinophilic esophagitis in a mammalian subject. Further provided are methods of monitoring the course of eosinophilic esophagitis in a subject diagnosed with the disease.Type: ApplicationFiled: April 4, 2011Publication date: July 4, 2013Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Leonard Franklin Pease, III, Kathryn Peterson, Gerald J. Gleich
-
Patent number: 8470528Abstract: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.Type: GrantFiled: April 30, 2010Date of Patent: June 25, 2013Assignee: The Board of Regents of the University of Texas SystemInventors: Renata Pasqualini, Wadih Arap, Juri Gelovani, Frank C. Marini, III, Amin Hajitou, Mian Alauddin, Martin Trepel
-
Publication number: 20130115166Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.Type: ApplicationFiled: July 20, 2011Publication date: May 9, 2013Applicant: CEPHALON AUSTRALIA PTY LTD.Inventors: Adam William Clarke, Anthony G. Doyle, Matthew Pollard, Stephen Tran
-
Publication number: 20130064763Abstract: Anti-ICAM-1 VHH single-domain antibodies (sdAbs) are generated by immunizing a llama with recombinant ICAM-1. These antibodies are linked to an imaging moiety for in vivo or ex vivo imaging of ICAM-1-related pathological conditions including atherosclerotic plaques. The antibodies may also be linked to a therapeutic agent to specifically target and treat ICAM-1-related pathological conditions.Type: ApplicationFiled: April 27, 2011Publication date: March 14, 2013Inventors: Abedelnasser Abulrob, Mehdi Arbabi-Ghahroudi, Danica Stanimirovic
-
Patent number: 8367040Abstract: Contrast agents comprising a scaffold protein having at least one operative integrated metal ion binding site.Type: GrantFiled: April 20, 2012Date of Patent: February 5, 2013Assignee: Georgia State University Research Foundation, Inc.Inventors: Jenny Jie Yang, Zhi-Ren Liu
-
Publication number: 20130028836Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.Type: ApplicationFiled: February 4, 2011Publication date: January 31, 2013Applicant: MORPHOTEK, INC.Inventors: Abdellah Sentissi, Douglas B. Jacoby
-
Patent number: 8304388Abstract: The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A precursor for the preparation of the imaging agent is also provided by the invention, as well as a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition which comprises fibrosis is provided.Type: GrantFiled: May 25, 2007Date of Patent: November 6, 2012Assignee: GE Healthcare LimitedInventors: Salah Chettibi, Ben Newton, Mette Husbyn, Magne Solbakken, Peter Brian Iveson, Rajiv Bhalla, Daniel Kramer, Jane Brown
-
Publication number: 20120244070Abstract: Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.Type: ApplicationFiled: March 25, 2011Publication date: September 27, 2012Inventors: Zheng-Rong LU, Xueming Wu
-
Publication number: 20120244080Abstract: Glucagon-like peptide-1 (GLP-1) is a member of a large family of incretin hormones secreted in nutrient-dependent response. GLP-1 acts on GLP-1 receptor (GLP-1 R) that is highly expressed on pancreatic ?-cells. The peptide has great potential for development of diabetes treatment and diagnosis. However, the pharmaceutical effects of the peptide suffer from in vivo instability and short life due to degradation by Dipeptidylpeptidase-1 (DPP-4). The 30 amino acid peptide GLP-1 has been integrated into a stable host protein human calbindin D9k. The fusion protein binds to GLP-1 R as demonstrated by immunostaining analyses of GLP-1 R expressing cells. The fusion protein agents can be useful for both diabetes treatment and GLP-1 R receptor targeting MR imaging. The fusion protein has a size about 14 kDa, which enables efficient tissue penetration and retention, and an extended circulation time, is stable, remaining intact and retaining activity after 48 hours incubation with 75% human serum.Type: ApplicationFiled: October 20, 2010Publication date: September 27, 2012Inventors: Zhi-Ren Liu, Jie Yang, Bing Xu, Wangda Zhou, Shenghui Xue
-
Patent number: 8252267Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of diseases, including cancer. The invention provides novel splice products of human DKKL-1 gene. The present invention provides methods of using polynucleotides having the novel splice products of the human DKKL-1 sequences, their corresponding gene products and modulators of the DKKL-1 splice products for the detection, diagnosis, prevention and/or treatment of associated cancers.Type: GrantFiled: March 30, 2006Date of Patent: August 28, 2012Assignee: Sagres Discovery, Inc.Inventors: Albert Lai, Robert Booher
-
Publication number: 20120195831Abstract: The present invention relates to Her3 specific antibodies, preferably fully human or humanized antibodies and antigen-binding portions thereof. Nucleic acid molecules encoding the Her3 antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with aberrant expression of Her3 or Her2 including aberrant activation of each of these receptors.Type: ApplicationFiled: October 7, 2010Publication date: August 2, 2012Inventors: Ningyan Zhang, Hans Huber
-
Publication number: 20120121507Abstract: Peptides are disclosed that are useful for molecular imaging or diagnosis of a disease state, such as cancer, in which clusterin is upregulated.Type: ApplicationFiled: April 15, 2010Publication date: May 17, 2012Inventors: Rana Filfil, Dmitri Tolkatchev, Feng Ni, Maureen D. O'Connor-McCourt, Anne E. G. Lenferink
-
Publication number: 20120114565Abstract: Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG.Type: ApplicationFiled: July 23, 2010Publication date: May 10, 2012Applicant: ADVANCED ACCELERATOR APPLICATIONS S.A.Inventors: Luca Domenico D'Andrea, Carlo Pedone, Maria Caterina Turco
-
Patent number: 8173105Abstract: Contrast agents comprising a scaffold protein having at least one operative integrated metal ion binding site.Type: GrantFiled: July 13, 2006Date of Patent: May 8, 2012Assignee: Georgia State University Research FoundationInventors: Jenny J. Yang, Zhi-Ren Liu
-
Publication number: 20120100070Abstract: Compositions, methods of using and methods of making a cyclic peptide analog imaging agent that includes at least portions of a peptide or protein that binds specifically to the GLP-1 receptor (GLP-1R) and the cyclic analog has one or more conformational restrictions including, but not limited to, lactam bridges, disulfide bridges, hydrocarbon bridges, and their combinations, salts and derivatives thereof wherein the cyclic analog is more stable than a non-cyclic analog when incubated in the presence of enzymes that degrade GLP-1 and have an increased serum half-live, wherein the cyclic analog comprises at least a portion of a GLP-1 peptide or at least a portion of an Exendin peptide salts, derivatives or combinations thereof.Type: ApplicationFiled: April 6, 2010Publication date: April 26, 2012Applicant: Board of Regents, The University of Texas SystemInventors: Jung-Mo Ahn, Xiankai Sun
-
Publication number: 20120093734Abstract: Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma are disclosed. A method for identifying cell-surface proteins, which are transmembrane proteins or proteins with a signal peptide and which are over-expressed in colorectal cancer (CRC) is disclosed. Biomarkers found with this method, diagnostic methods using them and contrast agents directed to them for use in magnetic resonance imaging (MRI) and/or magentic photon imaging (MPI) are disclosed. The methods and biomarkers allow for differentiating progressive (high-risk) CRC (adenocarcinomas) from non-progressive (low-risk) colorectal adenomas.Type: ApplicationFiled: March 31, 2010Publication date: April 19, 2012Applicant: VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETTENSCHAPPELIJK ONDERZOEK EN PATIENTENZORGInventors: Meike De Wit, Remondus Johannes Adriaan Fijneman, Cornelia Ramona Jimenez, Gerrit Albert Meijer
-
Publication number: 20120093733Abstract: In one embodiment, a biotag for targeting a cancer biomarker is provided. The biotag may include a cancer biomarker binding domain, an internalization domain, an endosomal escape domain, a lysosomal escape domain, a reporter binding domain, and a reporter, wherein the reporter is a diagnostic agent. In some aspects, the cancer biomarker is ERBB 1-4, EGFRvIII or Transferrin Receptor (TfR). In other aspects, the binding domain is an scFv, an sdFv, a CDR or an SDR modified CDR. In some aspects, the reporter binding domain is a metal binding domain, which may be chelated to a metal nanoparticle tag. In some aspects, the metal nanoparticle tag is a noble metal, a superparamagnetic metal, a core-shell nanoparticle, or a fluorescent agent. In another embodiment, a targeted contrast composition for use with a diagnostic imaging technique is provided, which includes a contrast agent and a biotag for targeting a cancer biomarker.Type: ApplicationFiled: May 24, 2011Publication date: April 19, 2012Inventors: Marek Malecki, Raf Malecki
-
Publication number: 20120039801Abstract: Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide—Antibody Fc domain fusion proteins and methods of their use are disclosed.Type: ApplicationFiled: December 7, 2009Publication date: February 16, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20120034158Abstract: An immuno-imaging agent for the detection of tumor cells by means of an immuno-imaging technique, including at least one of: an anti-Met monoclonal antibody, a fragment of an anti-Met monoclonal antibody containing the epitope binding region thereof, a genetically engineered antibody containing the epitope binding region of an anti-Met monoclonal antibody, a humanized antibody containing the epitope binding region of an anti-Met monoclonal antibody, or combinations thereof, wherein the anti-Met monoclonal antibody is produced by the hybridoma cell line ICLC PD 05006, and corresponding compositions and kits.Type: ApplicationFiled: July 14, 2011Publication date: February 9, 2012Inventors: Paolo Maria Comoglio, Paolo Carminati, Guus Van Dongen
-
Publication number: 20120009123Abstract: The invention provides compositions and methods for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to an albumin binding peptide and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 7, 2009Publication date: January 12, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20110311446Abstract: A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed.Type: ApplicationFiled: July 14, 2011Publication date: December 22, 2011Applicants: Bracco Suisse SA, Dyax Corp.Inventors: Daniel T. Dransfield, Aaron Sato, Robert Charles Ladner, Palaniappa Nanjappan
-
Patent number: 8071323Abstract: Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided.Type: GrantFiled: April 6, 2007Date of Patent: December 6, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu